What is Foresight Diagnostics?
Foresight Diagnostics is a privately-held company specializing in cancer diagnostics. It has developed a highly sensitive liquid biopsy testing platform designed for the measurement of minimal residual disease (MRD). This platform boasts a detection limit below 0.0001%, offering a significant improvement over existing tests. The technology is broadly applicable across various cancer types, providing physicians and biopharmaceutical companies with actionable insights for more personalized patient treatment strategies. The company's focus on advanced MRD detection positions it at the forefront of precision oncology.
How much funding has Foresight Diagnostics raised?
Foresight Diagnostics has raised a total of $104.3M across 3 funding rounds:
Series A
$12.5M
Series B
$58.8M
Series B
$33M
Series A (2021): $12.5M with participation from Pear Ventures, Civilization Ventures, and Bluebird Ventures
Series B (2023): $58.8M led by Bluebird Ventures, Foresite Capital, and Pear Ventures
Series B (2024): $33M supported by Stanford University, Pear VC, Agent Capital, Foresite Capital, Civilization Ventures, and Bluebird Ventures
Key Investors in Foresight Diagnostics
Stanford University
Stanford University, founded in 1891, is a world-renowned research institution known for its entrepreneurial spirit and contributions to innovation, particularly in its proximity to Silicon Valley. It fosters interdisciplinary approaches across a wide range of academic fields.
Pear VC
Pear VC is an early-stage venture capital firm that focuses on pre-seed and seed investments, supporting founders with talent recruitment, fundraising, and go-to-market strategies to foster startup growth.
Agent Capital
Agent Capital is a healthcare venture capital firm dedicated to investing in novel therapeutics and treatments for unmet patient needs, with a focus on oncology, rare diseases, neurology, and immunology.
What's next for Foresight Diagnostics?
With the recent influx of major strategic investment, Foresight Diagnostics is poised for significant expansion. The company is likely to channel these resources into further research and development, enhancing the sensitivity and scope of its liquid biopsy platform. Strategic partnerships with biopharmaceutical firms for clinical validation and commercialization are anticipated. Furthermore, the capital may support scaling manufacturing capabilities and expanding its sales and marketing efforts to penetrate new markets. This funding round signals strong investor confidence in Foresight Diagnostics' potential to revolutionize cancer monitoring and treatment.
See full Foresight Diagnostics company page
